Cambridge Healthtech Institute’s Inaugural
Characterization of ADCs, Bispecifics and New Biotherapeutics
Improving Prediction, Screening and Characterization of New Biologics
January 19-20, 2015
With the wave of new biotherapeutics formats flooding the discovery and development pipelines, there is an increasing need for better and faster characterization tools and strategies, and improved biomolecular and biophysical assays for the new biotherapeutics. The new Characterization of ADCs, Bispecifics and New Biotherapeutics conference presents high-level case studies and strategies on improving characterization of ADCs, bispecifics and novel protein formats. Cutting-edge tools, research findings and unpublished data will be featured at this forum.
We invite you to join colleagues in this discussion of the key challenges and solutions improving prediction, screening and characterization of new biologics, and see how experts like you are developing scientifically sound formulations of new biotherapeutics.
Developability Assessment for Protein Therapeutics
Stanley Krystek, Ph.D., Senior Principal Scientist, Computer Assisted Drug Design, Bristol-Myers Squibb Co.
Regulatory Perspective on Challenges in ADC Development
Wen Jin Wu, M.D., Ph.D., Senior Investigator, Division of Monoclonal Antibodies, Office of Biotechnology Products, OPS-CDER-FDA
High-Throughput Developability Screening Methods Targeting Antibody Self/Cross Interaction
Eric Krauland, Ph.D., Senior Director, Antibody Discovery and Optimization, Adimab, LLC
Analytical Characterization of Biologics for Candidate Selection and Optimization: Strategies and Case Studies
Guodong Chen, Ph.D., Principal Scientist, Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb Co.
Challenges in ADC Characterization
Shrikant Deshpande, Ph.D., Senior Director, Protein Chemistry, Biologics Discovery California, Bristol-Myers Squibb Co.
Analytical Characterization of ADCs in Early Phase Development
Maureen Fitch Bruhns, Ph.D., Senior Scientist, Analytical Development, Process Development, Igenica Biotherapeutics
Physical Characterization of ADC with Different Loadings
Jianxin Guo, Principal Scientist, Pfizer, Inc.
ADCs Based on RNA Polymerase II Inhibiting Toxins
Andreas Pahl, Ph.D., CSO, Heidelberg Pharma
Addressing Product Heterogeneity Challenges in ADC Biotherapeutics
Nomalie Jaya, Ph.D., Senior Scientist, Seattle Genetics, Inc.
Challenges and Strategies for Establishing an Analytical Control Strategy for Novel Complex Recombinant Biotherapeutics
Johnson Varghese, Senior Director, Head of Analytical Development, Shire HGT
Case Study of Grid Selection to Identify Bispecific Antibodies
Haiyan Jiang, Ph.D., Principal Scientist, Biologics Research, Janssen R&D
Analytical Challenges of Next-Generation Biotherapeutics
Hubert Kettenberger, Ph.D., Principal Scientist, Large Molecule Research, Roche Diagnostics GmbH
Analytical Characterization of Protein-Peptide Conjugates to Support Selection and Optimization of Two Therapeutic Vaccine Candidates: Challenges and Case Studies
Qiong (Joan) Guo, Ph.D., Senior Principal Scientist and Analytical Group Leader, Vaccine Immunotherapeutics Research Unit, Pfizer, Inc.